John D. Quisel Sells 34,800 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) CEO John D. Quisel sold 34,800 shares of the stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $55.33, for a total value of $1,925,484.00. Following the completion of the sale, the chief executive officer owned 161,828 shares of the company's stock, valued at approximately $8,953,943.24. This trade represents a 17.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Disc Medicine Price Performance

IRON stock traded down $1.09 during trading on Friday, hitting $56.91. The company had a trading volume of 275,330 shares, compared to its average volume of 338,853. The firm has a market capitalization of $1.97 billion, a price-to-earnings ratio of -14.52 and a beta of 0.76. The business has a 50 day moving average of $50.05 and a 200 day moving average of $51.80. Disc Medicine, Inc. has a fifty-two week low of $30.82 and a fifty-two week high of $68.73. The company has a current ratio of 37.65, a quick ratio of 37.65 and a debt-to-equity ratio of 0.04.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.03). As a group, research analysts predict that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Wedbush restated an "outperform" rating and set a $90.00 price objective on shares of Disc Medicine in a research note on Monday, June 16th. Morgan Stanley assumed coverage on Disc Medicine in a research note on Thursday, July 3rd. They set an "overweight" rating and a $85.00 price objective for the company. BMO Capital Markets raised their price objective on Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a research note on Monday, May 12th. HC Wainwright restated a "buy" rating and set a $118.00 price objective on shares of Disc Medicine in a research note on Thursday, July 3rd. Finally, Cantor Fitzgerald raised their price objective on Disc Medicine from $99.00 to $132.00 and gave the company an "overweight" rating in a research note on Tuesday, March 18th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Disc Medicine currently has a consensus rating of "Buy" and an average price target of $96.70.

Institutional Investors Weigh In On Disc Medicine

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC acquired a new stake in Disc Medicine during the 4th quarter worth about $5,479,000. Rhumbline Advisers raised its holdings in Disc Medicine by 10.7% during the 1st quarter. Rhumbline Advisers now owns 32,144 shares of the company's stock worth $1,596,000 after buying an additional 3,108 shares during the period. GAMMA Investing LLC raised its holdings in Disc Medicine by 5,092.5% during the 1st quarter. GAMMA Investing LLC now owns 12,410 shares of the company's stock worth $616,000 after buying an additional 12,171 shares during the period. Ameriprise Financial Inc. acquired a new stake in Disc Medicine during the 4th quarter worth about $335,000. Finally, Deutsche Bank AG raised its holdings in Disc Medicine by 75.7% during the 4th quarter. Deutsche Bank AG now owns 16,093 shares of the company's stock worth $1,020,000 after buying an additional 6,933 shares during the period. 83.70% of the stock is owned by institutional investors and hedge funds.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.